Adelaide midfielder Rory Sloane joins Gameday
In the latest win for Impression Healthcare’s (ASX:IHL) wholly owned subsidiary Gameday International, the company today announced its newest ambassador – Adelaide Football Club midfielder Rory Sloane, who made his AFL debut in 2009 and has won numerous industry awards in his career to date.
Sloane will promote Gameday mouthguards through his professional profile and social media channels, providing greater exposure and product awareness to AFL fans. He will also promote the Gameday Challenge, a grassroots activity camp for children held during school holidays.
In his role as ambassador he joins fellow AFL players Gary Ablett Junior, Moana Hope and Katlyn Ashmore and professional rugby league player Matt Ballin in promoting the products as well as a broader campaign to encourage youth participation in sport.
Under the three-year contract, Sloane will have his own range of mouthguard designs including a limited edition range, similar to the deal signed by Ablett in December. As part of the deal Sloane will be issued 270,270 shares in the company.
“I’m excited to encourage more kids to become involved with the sport and it’s great that Gameday gives me a platform to do this,” Mr Sloane said.
“Having played professional AFL for many years, I speak from personal experience when I say it’s important to have the right protective gear that is comfortable and effective.
“It’s great that Gameday has made a custom-fit, professional standard mouthguard which is both affordable and easily accessible to everyday Australians so that they don’t need to compromise on safety or comfort when playing sports where protection is key.”
The appointment of Sloane as ambassador coincides with a range of marketing initiatives the company will implement ahead of the 2017 sporting season, with the hope of driving sales revenue in 2017.
Although, it should be noted that broker projections and price targets are only estimates and may not be met. Also, historical data in terms of earnings performance and/or share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.